ELLIPSES PHARMA

Ellipses Pharma is a drug development company focused on accelerating the availability of cancer medicines and treatments. The company was founded in 2015 by Professor Sir Chris Evans and Dr. Rajan Jethwa, who serve as Chairman and CEO, respectively. Sir Chris Evans is a renowned biotech entrepreneur with a track record of founding over 50 life sciences companies, including several that achieved unicorn status.

The company's business model centers on in-licensing promising clinical candidates from biotech companies, academic institutions, and pharmaceutical partners. Ellipses then leverages a unique drug development model that combines unbiased vetting of assets, uninterrupted funding, and expert oversight to accelerate clinical trials. A key component of this model is the Scientific Affairs Group, a network of over 300 global oncology key opinion leaders who provide independent, unbiased expertise to de-risk asset selection and optimize clinical trial design. This approach aims to reduce R&D costs and enhance the probability of success.

Instead of seeking funding for individual trials, Ellipses capitalizes the company as a whole, ensuring that capital is allocated to in-licensed assets as needed, which streamlines the development process. Once a drug has progressed through trials and reached a key value inflection point, typically during or after Phase II, the model is to out-license the asset to larger pharmaceutical companies equipped for late-stage development and commercialization. The company's pipeline includes small molecules, large molecules, and nanoparticle drug conjugates. One notable asset is EP0031/A400, a next-generation selective RET inhibitor for treating RET-altered tumors, which is being developed globally in partnership with Kelun-Biotech.

Keywords: oncology drug development, cancer treatments, clinical trial acceleration, drug in-licensing, asset out-licensing, clinical candidate vetting, oncology therapeutics, biotech investment, pharmaceutical partnerships, RET inhibitor, immuno-oncology, nanoparticle drug conjugate, EP0031, A400, vosilasarm, EP0062, EP0057